← Back to Patent Explorer
US4788202A Expired / Lapsed US ⏱️ 0.0 years remaining

Sulphonamide derivatives as α2 -adrenoceptor antagonists

Assignee: John Wyeth and Brother Ltd
•
Filing: 1987-07-09
•
Granted: 1988-11-29
•
Expires: 2007-07-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention concerns sulphonamides of general formula ##STR1## and their pharmaceutically acceptable acid addition salts. In formula (I), R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or aryl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl). The compounds possess α 2 -adrenoceptor antagonistic activity in warm blooded animals.

Inventors

  • 👤 Terence J. Ward

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:00
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/12; C07D471/14; A; A61; A61P; A61P25/00; A61P25/02; C07D491/00; C07D491/12; C07D491/14; C07D495/00; C07D495/12; C07D495/14

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 131 words
A compound selected from the group consisting of a sulphonamide of the formula (I) ##STR11## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or pheny substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 2
Dependent Claim 131 words
A compound selected from the group consisting of a sulphonamide of the formula (I) ##STR11## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or pheny substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 3
Dependent Claim 11 words
A compound as claimed in claim 1 wherein A is ethylene.
Claim 4
Dependent Claim 18 words
A compound according to claim 1 which is N-[(2β, 12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)methanesulphonamide or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim 29 words
A compound according to claim 1 which is N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(-2-ethanesulphonamidoethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-indolo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamido)ethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-indolo[2,3-a]quinolizin-2-yl]-N(-2-ethanesulphonamidoethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo [2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl) benzenesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)-p-methylbenzenesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]thieno[2,3-a]-quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)methanesulphonamide or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim 155 words
A pharmaceutical composition having α 2 -adrenoceptor antagonistic activity comprising an amount effective to antagonise α 2 -adrenoceptors of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR12## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl) and a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 155 words
A pharmaceutical composition having α 2 -adrenoceptor antagonistic activity comprising an amount effective to antagonise α 2 -adrenoceptors of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR12## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl) and a pharmaceutically acceptable carrier.
Claim 8
Independent Claim 152 words
A method of antagonising α 2 -adrenoceptors in warm blooded animals which comprises administering to the animal an effective amount of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR13## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 9
Independent Claim 152 words
A method of antagonising α 2 -adrenoceptors in warm blooded animals which comprises administering to the animal an effective amount of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR13## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 10
Dependent Claim 82 words
A compound of formula (XIII) ##STR14## or an acid addition salt thereof, wherein R, R 1 , R 2 , X and A are as defined in claim 1 and Z 1 and Z 2 are both hydrogen or Z 1 is hydrogen and Z 2 is SO 2 R 4 (where R 4 is as defined in claim 1) or Z 1 is SO 2 R 3 (where R 3 is as defined in claim 1) and Z 2 is hydrogen.

References Cited (Backward Citations)

EP0154142A1 Cited
US4690928A Cited
US4640924A Cited
US4686226A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-11-29 1992-05-30 1992-11-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-11-29 1996-05-30 1996-11-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-11-29 2000-05-30 2000-11-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag